MicrofluidX is an award-winning startup developing a break-through bioprocessing platform for the CGT market, based on microfluidic technology. Its platform allows ultra-low costs and scaleup of CGT from discovery to commercial stages, making these very potent treatments affordable for a wider number of patients, and reducing development times by several years. MicrofluidX is currently developing a system that will allow biologists to test dozens of cell culture conditions in parallel in an automated way replacing the Petri dish, the flask, the bag, the bioreactor, and the centrifuge all at once! More details on the role in the link